Ms. Sandra  Leung Esq.

Executive Vice President & Gen. Counsel

Mr. Rupert  Vessey BCH, BM, DPHIL, M.A.

Executive Vice President & Pres of Research

Executive Vice President and Pres of Research & Early Devel.

Dr. Giovanni  Caforio M.D.

Chairman & Chief Executive Officer

Dr. Christopher S. Boerner

Executive Vice President & Chief Commercialization Officer

Mr. Jitendra  Tyagi

Head of US Drug Makers - India

Mr. David V. Elkins

Executive Vice President & Chief Financial Officer

Ms. Cari  Gallman

Senior Vice President & Chief Compliance and Ethics Officer

Mr. Timothy  Power

Vice President & Head of Investor Relations

Ms. Ann M. Powell Judge

Executive Vice President & Chief HR Officer

Dr. Fouad  Namouni M.D.

Head of Oncology Devel.

Mr. Greg  Meyers

Executive Vice President and Chief Digital & Technology Officer

Dr. Christopher S. Boerner Ph.D.

Executive Vice President & Chief Operating Officer

Chief Operating Officer

Executive Vice President, Chief Operating Officer & Director

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Sarat Sethi, DCLA managing partner and portfolio manager, joins 'Squawk Box' to discuss the latest market trends, his top undervalued stock picks, and more.

DCLA's Sarat Sethi reveals the best undervalued stocks to buy right now

Bristol-Myers Squibb Company (NYSE:BMY ) 2023 Virtual ASCO Investor Event Conference June 6, 2023 8:00 AM ET Company Participants Tim Power - Investor Relations Samit Hirawat - Chief Medical Officer Adam Lenkowsky - Chief Commercialization Officer Lynelle Hoch - Senior Vice President, Cell Therapy Franchise Lead Rosanna Ricafort - Vice President Cell Therapy Clinical Development Lead Conference Call Participants Chris Schott - JPMorgan Carter Gould - Barclays Matt Phipps - William Blair Dane Leone - Raymond James Terence Flynn - Morgan Stanley Steve Scala - TD Cowen Adam Jolly - Wolfe Research Hao Shen - Bank of America Harry Gillis - Berenberg Olivia Brayer - Cantor Tim Power Good morning. This is Tim Power from Bristol-Myers Squibb Investor Relations.

Bristol-Myers Squibb Company (BMY) Presents at 2023 Virtual ASCO Investor Event Conference (Transcript)

Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy of Opdivo plus Yervoy.

Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study

Bristol Myers Squibb (BMY) is an undervalued pharmaceutical stock with strong positioning in cardiovascular, oncology, and immunology sectors. BMY has a strong balance sheet, high margins, and a pipeline of newer drugs, making it an attractive long-term investment. BMY stock offers a well-covered 3.5% dividend yield and has a consensus Buy rating from analysts, with an average price target of $79.

Bristol Myers Squibb: Take The Red Pill

Bristol Myers Squibb is a biopharmaceutical industry stalwart that pays a high dividend. Gilead Sciences' valuation is cheap, and its dividend continues to grow.

3 Dividend Stocks You Can Buy Without Any Hesitation

Bristol-Myers CEO Giovanni Caforio to Step Down 

Bristol Myers Profit Tops Estimates but Revenue Falls on Lower Revlimid Sales

Bristol Myers, Carvana, MicroStrategy, Adobe, and More Stock Market Movers

Bristol Myers Stock Falls After Stroke Medicine Misses the Mark

Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall

Drugmakers Hope New Heart Drugs Boost Sales, Revive Market

Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion 

Buy Bristol Myers Stock. Its Rally Is Just Getting Started.

Bristol Shares Fall Despite New Heart Drug as Company Cuts Forecasts

FDA Approves New Bristol-Myers Drug for Common Inherited Heart Disease 

Bristol Stock Inches Up After Earnings. It's Beating the Market in 2022.

Bristol Stock Is Too Cheap. Why It Could Be Ready to Rally.

Bristol Myers Squibb Stock Rises After Modest Earnings Beat

Powered by AI

Bristol-Myers Squibb Company

65.31